Company intelligence
Immatics
The Global Leader in Precision Targeting of PRAME
About Immatics
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/
Verified activity
Signals from Immatics
3 published signals
Presence & Recognition
Immatics attended the inaugural SITC EU Immuno-Oncology Drug Development Summitt in Lausanne, which was the first time the Society for Immunotherapy of Cancer (SITC) organized a conference in Europe.
Reported by Cedrik M. Britten
Presence & Recognition
Immatics is looking forward to sharing progress toward its mission of developing and delivering novel PRAME-targeted immunotherapies for patients with cancer.
Reported by Immatics
Presence & Recognition
Immatics CMO Cedrik M. Britten will present clinical data on TCR T-cell therapy and bispecific T-cell engagers targeting PRAME+ cancers at the SITC EU Immuno-Oncology Drug Development Summit on September 3, 2026.
Reported by Immatics